Biolase, Inc. · OTC:BIOLQ
Biolase — Biolase Technology — 13th Annual B. Riley & Co. Investor Conference (May 2012)
24 slides from Biolase's conference presentation, May 23, 2012
Slide 1: Fred Furry, COO & CFO
Exhibit 99.1 Fred Furry, COO & CFO NASDAQ: BLTI www.biolase.com PAGE 1
Slide 2: Safe Harbor Statement
Safe Harbor Statement This presentation may contain forward-looking statements that are based on our current expectations, estimates and projections about our industry as well as management’s beliefs and assumptions. Words such as “anticipates,” “expects,” “intends,” “plans,” “believes,” “seeks,” “e
Slide 3: BIOLASE is Revolutionizing Surgery in Medicine
BIOLASE is Revolutionizing Surgery in Medicine How? Through the science of WaterLase! Conventional Surgical Devices include the scalpel, high speed drill, electrosurge, electric bone saws, and heat generating lasers. What is Waterlase? • BIOLASE has invented and perfected a biological method to cut
Slide 4: Becoming a Globally Diversified Platform Company
Becoming a Globally Diversified Platform Company In 2011, we implemented our turnaround as We are moving forward to broaden our addressable essentially a single product company: platforms and product portfolio 1. Moved from global exclusive distribution model1.withContinue to diversify our revenue b
Slide 5: Traditional Dentistry
Traditional Dentistry The painting Cavadenti, the Tooth Puller, by Caravaggio, circa 1608 PAGE 5
Slide 6: BIOLASE is the World Leader in Laser Dentistry
BIOLASE is the World Leader in Laser Dentistry …with nearly 20,000 lasers sold worldwide, including our revolutionary iPlus, which was launched in the first quarter of 2011: The aiming beam on The iPlus features an the WaterLase does intuitive, touch-based not cut the tissue or computer screen, gene
Slide 7: WaterLase High Speed Cutting
WaterLase High Speed Cutting PAGE 7
Slide 8: WaterLase Side by Side with Drill
WaterLase Side by Side with Drill PAGE 8
Slide 9: WaterLase Soft Tissue Lingual Frenectomy
WaterLase Soft Tissue Lingual Frenectomy PAGE 9
Slide 10: Current Line of BIOLASE Products
Current Line of BIOLASE Products All-tissue dental lasers: Ourall-tissuelasersincludeourflagshiplaser,therevolutionary WaterLase iPlus, and the new WaterLase MDX 450 and 300. Diode soft-tissue dental lasers: Oursofttissuelasers include the revolutionary iLase, a portable diode laser with no foot ped
Slide 11: Why Dentists Should Buy a WaterLase System?
Why Dentists Should Buy a WaterLase System? …the tremendous Return on Investment! Monthly Lease Payment New Monthly Revenue Generated Approx. $1,200 $5,000 – $15,000 • WaterLase technology enables traditional dentists to perform procedures that they currently refer out to specialists or current Wate
Slide 12: Warning: Patients Urged to Ask their Dentists About the Risk of Cross Contamination!
Warning:Patients Urged to Ask their Dentists About the Risk of Cross Contamination! Cross contamination is a huge 1,2,3,4 threat: • The CDC defines cross-contamination as the act of spreading bacteria and viruses from one surface to another. Blood-borne viruses have the ability to live on objects an
Slide 13: Eliminating the Risk of Cross Contamination
Eliminating the Risk of Cross Contamination BIOLASE is entering a new dental category utilizing WaterLase technology as it essentially eliminates the risk of cross contamination and contagion: Burs and Endo Files: WaterLase Tips: WaterLase MD™reduced E. faecalis 2.86 times more effectively than NaOC
Slide 14: $50B to $100B WaterLase Market Opportunity
$50B to $100B WaterLase Market Opportunity TheWaterLase’s globalmarketopportunity isimmense… because the dental community is the largest medical community in the world. Our current market penetration is approximately 3% in the US and slightly less than 1% internationally! 1 • 176,000dentistsin theUS
Slide 15: Patent Portfolio
Patent Portfolio Current Status: BIOLASE hasa tremendous IPportfoliowith285issuedandpendingpatents,70%of which are related to our core WaterLase (Er,Cr:YSGG) technology and medical lasers. Issued Pending Total U.S. 84 53 137 International 77 71 148 Total 161 124 285 Filingcostsandmaintenance areclos
Slide 16: Further Opportunities to Expand in Dentistry
Further Opportunities to Expand in Dentistry Patented laser toothbrush for home use: • BIOLASE is currentlyengagedindiscussions withTheProctorandGambleCompany (“P&G”)todevelopa laser toothbrush for home use using our patents which will whiten teeth, disinfect teeth and gums, bio- stimulateteethandgu
Slide 17: Digital Imaging
Digital Imaging ConeBeamComputed Tomography (CBCT)3DImaging:WeoffertheCefla NewTom VGi and the BIOLASE DaVinci D3D digital CBCTs. These systems are a vast improvement over traditional x-ray imaging technologies and offer tremendous clinical and diagnostic advantagesto dentists.CBCTsallowdentiststo“s
Slide 18: 2012: Expanding Beyond Dentistry
2012: Expanding Beyond Dentistry With our patented WaterLase and diode technologies, we have created technological platforms that have the ability to extend far outside of dentistry. We expect to greatly expand our addressable markets in thewhich, near future we believe, has the potential to substan
Slide 19: 2012: Expanding Beyond Dentistry (Continued)
2012:Expanding BeyondDentistry(Continued) Aesthetics: WehavevariousFDAapprovalsforapplications indermatology,plasticsurgery,and oculoplastics and are currently investigating options for entering these markets in 2012. PainManagement: Weanticipatelaunching a newdeep-tissue handpieceandupgraded diodel
Slide 20: Quarterly Revenues
QuarterlyRevenues (inMillions) $25.0 $20.0 Federico Pignatelli restored as Chairman & CEO in Aug 2010 $15.0 $10.0 Record quarter with Federico Pignatelli interim Over 85% revenue $5.0 CEO during Q407 growth in 2011 Direct sales ramp begins in Sep 2010compared to 2010 $- 2004 2005 2006 2007 2008 2009
Slide 21: Quarterly Non-GAAP Net Income
QuarterlyNon-GAAP NetIncome(inMillions) 2004 2005 2006 2007 2008 2009 2010 2011 2012 Q1-Mar $ 0.783 $ (4.015) $ (1.462) $ (0.890) $ 0.985 $ (3.763) $ (4.797) $ 0.153 $ (0.872) Q2-Jun $ 1.006 $ (6.222) $ (1.340) $ (0.089) $ 1.578 $ 3.020 $ (3.657) $ 0.069 Q3-Sep $ (0.962) $ (4.820) $ (0.167) $ (2.765
Slide 22: Chart & Financial History
Chart & Financial History 1994-Aug 2006 Pignatelli Exclusive distribution partnership with Henry Schein Aug 2010 to present Pignatelli Chairman of the Chairman of the Board Aug 2006–Aug 2010 Board and CEO $80,000 $70,000 $20 $60,000 $15 $50,000 $40,000 $10 $30,000 $20,000 $5 $10,000 $0 1998 1999 200
Slide 23: Executive Management
Executive Management Federico Pignatelli has served as our CEO since August 2010, and as our Chairman of the Board and CEO since September 2010. Mr. Pignatelli is a >5% shareholder and has been active in the Company as a director and various other management roles since 1991. He also the founder of
Slide 24: BIOLASE Today
BIOLASE Today • Our 57,000 sq. ft. corporate HQ in Irvine houses finance & administrative, sales, marketing, customer care, training, manufacturing, and R&D. This facility can accommodate growth to $250 million. • ISO 9001 certified and FDA GMP with white-room operations. Company Headquarters in Irv
Biolase Technology — 13th Annual B. Riley & Co. Investor Conference (May 2012) on 6ix